Q2 2025 saw a reversal of many first quarter factor trends. After lagging steeply in several regions in Q1, Momentum ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales ...